Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon
Surgeons in Houston have performed the world’s first successful human implant of BiVACOR’s Total Artificial Heart (TAH) technology. The procedure was completed July 9, 2024, at The Texas Heart Institute at Baylor St. Luke’s Medical Center. It was part of an early feasibility study (EFS) first approved by the U.S. Food and Drug Administration (FDA) back in December 2023.

Texas surgeons first in world to perform ‘groundbreaking’ total artificial heart procedure

The BiVACOR technology was designed to serve as a bridge to heart transplant in patients with end-stage heart failure. Based on rotary blood pump technology, it is made of titanium and approximately the size of an adult’s fist.

Restore Medical ContraBand medical device heart failure

FDA grants new heart failure implant its breakthrough device designation

Restore Medical's ContraBand system was designed to address symptoms in HFrEF patients who do not respond to other therapies. 

Adona Medical adjustable interatrial shunt

Heart failure startup raises $33.5M for adjustable interatrial shunt

Adona Medical’s adjustable interatrial shunt can be made larger or smaller in size after implantation through the use of a custom-designed induction catheter.

Zachary Kon, MD, surgical director, advanced heart failure and cardiac transplantation at Hofstra/Northwell, explains the current standard for collecting and preserving organs and a the new concept of thoracoabdominal normothermic regional perfusion (NRP)

Advances in heart transplantation: Normothermic regional perfusion and beyond

Zachary Kon, MD, discussed the current standard for preserving organs and how NRP could lead to even better outcomes.

the words "FDA recall" on a board

Abbott’s HeartMate LVADs recalled again over screen issues—FDA highlights significant risks

Abbott has received multiple reports of its HeartMate monitor screens freezing, glitching and even displaying incorrect patient information. A total of 17 injuries have been reported so far. 

Endotronix, an Illinois-based healthcare technology company, has gained U.S. Food and Drug Administration approval for its Cordella Pulmonary Artery (PA) Sensor System, which uses PA pressure-guided therapy to manage and treat heart failure patients.

FDA approves new pulmonary artery sensor for heart failure

The Cordella platform from Endotronix includes an implantable sensor that tracks the patient’s PA pressure and other helpful health data.

Thumbnail

Semaglutide improves heart failure symptoms in both sexes—weight loss greater in women

“Understanding the sex differences in obesity-related HFpEF is of great importance,” one cardiologist explained. “Obesity and visceral adiposity are key drivers of HFpEF development and progression, and this may be even more amplified in women."

Vivek Reddy, MD, Director, Cardiac Arrhythmia Service, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology, at Mount Sinai in New York, was involved in most of the late-breaking pulsed field ablation (PFA) trials at the Heart Rhythm Society (HRS) 2024 meeting. He offers an overview of the new data presented and his observations from using PFA. #HRS24 #HRS2024 #PFA #EPeeps

The future of electrophysiology: Reviewing key trends in PFA

Vivek Reddy, MD, was involved in most of the late-breaking pulsed field ablation trials at Heart Rhythm 2024. He spoke to Cardiovascular Business at the conference about those trials and what they mean going forward.

Displaying 49 - 56 of 672
Design by Adaptive Theme